Acute Bacterial Skin and Skin Structure Infections Market: Epidemiology Ana

DelveInsight's comprehensive report on "Acute Bacterial Skin and Skin Structure Infections Market Insights, Epidemiology and Market Forecast - 2034" delivers extensive understanding of Acute Bacterial Skin and Skin Structure Infections, encompassing historical and projected epidemiology alongside market dynamics in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Unlock key insights into the ABSSSI Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ ABSSSI Market Size

Key Highlights from the Market Report

• In September 2025, Melinta Therapeutics Inc. revealed an investigation to assess the safety and tolerability of 2 formulations of single-dose intravenous (IV) oritavancin diphosphate (Orbactiv and Kimyrsa) for treating pediatric participants diagnosed with acute bacterial skin and skin structure infections (ABSSSIs).

• The highest MRSA hospitalization rate was documented among elderly patients—360.8 MRSA stays per 100,000 patients over 65 years of age, representing more than three times the rate of any other age cohort: 114.7 stays for infants, 19.2 for 1- to 17-year-olds, 58.1 for 18- to 44-year-olds, and 111.5 for 45- to 64-year-olds per 100,000.

• According to secondary analysis, ABSSSI accounted for nearly 870,000 hospital admissions in the United States in 2004, representing approximately 30% increase in diagnostic incidence over a 4-year timeframe.

• Among approximately 5 million adult ABSSSI hospital admissions, with admissions increasing 17.3% from 2005-2011. ABSSSI patients were predominantly male (50.8%), white (60.3%), with mean age 55.7 years.

• According to DelveInsight's analysis, ABSSSI infection incidence demonstrates higher prevalence in males than females.

• Per analytical findings, the microorganisms most frequently isolated from SSTIs were Staphylococcus aureus (29.2%), Pseudomonas aeruginosa (11.9%), E. coli (8.9%) and Enterococcus faecalis (7.4%).

• Key pharmaceutical developers include Melinta Therapeutics, LLC, Merck, Pfizer, Allergan, Paratek Pharmaceuticals, Cumberland Pharmaceuticals, Teva Pharmaceuticals, and others.

• Notable investigational therapies comprise Contezolid acefosamil, Rifaquizinone (TNP-2092), and additional candidates.

Stay ahead in the competitive landscape of the ABSSSI Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ ABSSSI Treatment Market Size

Epidemiological Segmentation in the 7MM

• Total Incident Cases of ABSSSI community/hospital

• Acute Bacterial Skin and Skin Structure Infections Age-specific Incident Cases

• Acute Bacterial Skin and Skin Structure Infections Gender-specific Incident Cases

• Acute Bacterial Skin and Skin Structure Infections Pathogen-specific Incident Cases

Download the report to understand which factors are driving ABSSSI epidemiology trends @ ABSSSI Prevalence

ABSSSI Marketed Therapeutics

DALVANCE (dalbavancin): ABBVIE /Durata Therapeutics DALVANCE (dalbavancin), developed by Durata Therapeutics, represents a pioneering therapy targeting the fundamental cause of ABSSSI. FDA-approved in May 2014, DALVANCE is an intravenous long-acting lipoglycopeptide antibiotic. Its action mechanism involves targeting cell wall synthesis in Gram-positive bacteria through binding to the D-alanyl-D-alanine terminus of lipid II, a crucial precursor in this mechanism. Demonstrating effectiveness against a comprehensive spectrum of Gram-positive bacteria, including MRSA and Streptococcus pyogenes, DALVANCE exhibits bactericidal properties.

ORBACTIV: Melinta Therapeutics ORBACTIV, developed by The Medicines Company (currently part of Melinta Therapeutics), represents a substantial advancement in ABSSSI therapeutic management. FDA-approved, it provides an innovative approach to combating Gram-positive bacterial infections by suppressing bacterial cell wall synthesis, specifically through binding to the peptidoglycan precursor lipid II. With proven efficacy against various Gram-positive pathogens, including MRSA, ORBACTIV distinguishes itself through its unique pharmacokinetic characteristics, enabling once-daily administration. This convenience not only streamlines treatment protocols but also possesses the potential to improve patient adherence and enhance clinical outcomes in ABSSSI management.

Emerging ABSSSI Therapeutics

MRX-4: MicuRx MRX-4 represents an injectable novel oxazolidinone antibacterial agent for treating multidrug-resistant (MDR) infections, exhibiting potent activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and penicillin-resistant Streptococcus pneumoniae (PRSP). In September 2018, the US FDA conferred qualified infectious disease product status (QIDP) and fast track designation to contezolid acefosamil for acute bacterial skin and skin structure infections (ABSSSI) treatment. Currently, this compound is advancing through Phase III clinical development.

ZEVTERA (ceftobiprole): Basilea Pharmaceutica ZEVTERA, developed by Basilea Pharmaceutica, is an intravenous cephalosporin antibiotic demonstrating rapid bactericidal activity against a comprehensive bacterial spectrum, including MSSA, MRSA, and susceptible Pseudomonas spp. It currently holds approval for hospital-acquired pneumonia treatment. In August 2019, positive topline results from the TARGET study were announced, followed by comparably favorable outcomes from the ERADICATE study in June 2022. Subsequently, in April 2024, the US FDA granted approval for ceftobiprole's New Drug Application (NDA). This approval encompasses therapeutic indications for Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSI), as well as community-acquired bacterial pneumonia (CABP).

Discover the future of ABSSSI Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ ABSSSI Market Drivers and Barriers

Therapeutic Management Landscape

ABSSSI therapeutic management aims to alleviate symptoms, enhance quality of life, arrest disease progression, and prevent recurrence. Initial management approaches, according to IDSA guidelines, frequently involve oral antibiotics effective against streptococci for typical cellulitis presentations. However, MRSA prevalence has necessitated treatment strategy reevaluation. Major therapeutic options for mild non-purulent infection cases include penicillin, amoxicillin, amoxicillin-clavulanate, dicloxacillin, cephalexin, and clindamycin.

Market Landscape Analysis

The Acute Bacterial Skin and Skin Structure Infections pharmaceutical market for ABSSSI-targeted treatments is experiencing substantial growth, propelled by increasing infection incidence and rising antibiotic-resistant bacteria prevalence. Innovations in antibiotic therapies, encompassing novel agents and combination approaches, are expanding therapeutic options and accelerating market expansion. Additionally, growing emphasis on personalized medicine and rapid diagnostic technologies is optimizing ABSSSI management. Increased research and development investment by pharmaceutical organizations and the expanding market for advanced healthcare solutions contribute to the sector's robust growth trajectory. As healthcare systems address resistant infection challenges, demand for effective ABSSSI treatments is anticipated to continue rising.

Explore the dynamics of the ABSSSI Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ ABSSSI Ongoing Clinical Trials Analysis

Report Scope

• Geographic Coverage: Global

• Study Period: 2020-2034

• Featured Companies: Melinta Therapeutics, LLC, Merck, Pfizer, Allergan, Paratek Pharmaceuticals, Cumberland Pharmaceuticals, Teva Pharmaceuticals, and others

• Pipeline Therapies: Contezolid acefosamil, Rifaquizinone (TNP-2092), and others

• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

• Additional Coverage: Acute Bacterial Skin and Skin Structure Infections Unmet Needs, KOL's views, Analyst's views, Acute Bacterial Skin and Skin Structure Infections Market Access and Reimbursement

Table of Contents

1. Key Insights

2. Report Introduction

3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market Overview at a Glance

4. Epidemiology and Market Methodology

5. Executive Summary of ABSSSI

6. Key Event

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Therapies

11. Emerging Therapies

12. ABSSSI: Seven Major Market Analysis

13. Key Opinion Leaders' Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. Bibliography

19. Acronyms and Abbreviations

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight operates as a premier healthcare-focused market research and consulting organization, delivering high-caliber market intelligence and analytical insights that empower informed business decision-making. Supported by seasoned industry specialists and comprehensive expertise in life sciences and healthcare domains, the firm provides tailored research solutions and strategic insights to a global client base. Engage with our team to access premium-quality, precise, and current intelligence that positions you ahead of market developments.

Contact Us

Kanishk

kkumar@delveinsight.com